Lundbeck

IV drug delivery
Biotech

Lundbeck’s preventative migraine IV sees success in ph. 2

Based on the findings, the Danish pharma plans on discussing phase 3 design options with regulators.
Gabrielle Masson Feb 12, 2026 1:25pm
Takeda

Takeda inks $1.7B AI discovery deal with Iambic Therapeutics

Feb 9, 2026 8:00am
pivot change turnaround direction walk away

Lundbeck ends subcutaneous migraine cohort after futility review

Apr 1, 2025 5:00am
stop shut down close end button

Lundbeck slashes value of $250M Abide buyout after pain setback

Oct 24, 2024 7:20am
graphic of the brain and the electrical signals that make it up

Lundbeck signs $2.5B check for Longboard and its epilepsy med

Oct 14, 2024 8:30am
AI artificial intelligence drug development computational biology machine learning

Lundbeck taps Charles River for AI-enabled neuro drug discovery

Oct 2, 2024 9:21am